A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Male
Prostate Cancer
Male
Prostate Cancer
Trial Information
A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer
Inclusion Criteria:
- 18 years of age and older
- Histologically documented adenocarcinoma of prostate
- Currently receiving LHRH agonists with castrate levels of testosterone or who have
had an orchiectomy
- Must have had a rise in PSA despite anti androgen withdrawal
- Exhibit 2 consecutive rise in PSA after the last hormonal manipulation
- Minimum PSA of greater than 5 KPS greater than 80%
- Normal cortisol level at entry
- Life expectancy greater than 6 months
- Provide written consent pursuant to regulatory requirements prior to initiation of
study procedure
Exclusion criteria:
- Younger than 18 years
- Patients without prostate cancer
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Ability of oral triamcinalone given twice a day to patients with androgen independent prostate cancer to produce a sustained biochemical response.
Outcome Time Frame:
Following treatment
Principal Investigator
Sandy Srinivas, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Stanford University
Authority:
United States: Institutional Review Board
Study ID:
PROS0006
NCT ID:
NCT00186108
Start Date:
October 2002
Completion Date:
September 2005
Related Keywords:
- Prostate Cancer
- Oral Triamcinalone
- Prostate Cancer
- Prostatic Neoplasms
Name | Location |
|---|---|
| Stanford University Cancer Center | Stanford, California 94305 |
